Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$60.8M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$35.8M |
| 3 |
Roivant Sciences
ROIV
|
+$33.4M |
| 4 |
KYNB
Kyntra Bio
KYNB
|
+$26.7M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$605M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$395M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$110M |
| 4 |
Travere Therapeutics
TVTX
|
+$25.8M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$25.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Immatics
IMTX
$1.22B
| $35.8M | 0.19% |
5,187,081
| – | – |
|
|
27
Roivant Sciences
ROIV
$26.2B
| $35.3M | 0.19% |
4,777,430
+4,060,777
| +567% | +$33.4M |
|
28
Nurix Therapeutics
NRIX
$2.77B
| $34.5M | 0.19% |
3,882,125
| – | – |
|
|
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $33.7M | 0.18% |
1,455,202
-1,078,900
| -43% | -$25.7M |
|
30
Kiniksa Pharmaceuticals
KNSA
$6.17B
| $30.1M | 0.16% |
2,799,577
| – | – |
|
|
DICE
31
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $29.7M | 0.16% |
1,035,786
+173,579
| +20% | +$5.14M |
|
32
Xenon Pharmaceuticals
XENE
$5.88B
| $26.9M | 0.15% |
751,639
| – | – |
|
|
TSVT
33
DELISTED
2seventy bio
TSVT
| $25.5M | 0.14% |
2,497,526
+434,782
| +21% | +$4.97M |
|
34
Denali Therapeutics
DNLI
$3.98B
| $25.1M | 0.14% |
1,088,738
| – | – |
|
|
DBVT
35
DBV Technologies
DBVT
$914M
| $24.7M | 0.13% |
1,461,426
| – | – |
|
36
Krystal Biotech
KRYS
$10.3B
| $24.2M | 0.13% |
302,716
| – | – |
|
|
VERV
37
DELISTED
Verve Therapeutics
VERV
| $20.4M | 0.11% |
1,416,530
| – | – |
|
38
Ultragenyx Pharmaceutical
RARE
$2.55B
| $18.9M | 0.1% |
470,974
| – | – |
|
|
BCYC
39
Bicycle Therapeutics
BCYC
$306M
| $17.9M | 0.1% |
843,814
| – | – |
|
40
Stoke Therapeutics
STOK
$2.08B
| $17.6M | 0.1% |
2,115,416
+1,006,503
| +91% | +$9.08M |
|
41
AnaptysBio
ANAB
$1.71B
| $16.9M | 0.09% |
775,924
| – | – |
|
|
RNAM
42
DELISTED
Avidity Biosciences
RNAM
| $15.4M | 0.08% |
1,004,051
+569,269
| +131% | +$12.5M |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $15M | 0.08% |
+333,665
| New | +$15M |
|
44
ARS Pharmaceuticals
SPRY
$547M
| $13.1M | 0.07% |
2,006,451
| – | – |
|
45
Pacific Biosciences
PACB
$420M
| $13.1M | 0.07% |
1,127,782
| – | – |
|
46
Prime Medicine
PRME
$615M
| $12.7M | 0.07% |
1,028,466
| – | – |
|
47
Heron Therapeutics
HRTX
$60.4M
| $12.3M | 0.07% |
8,131,678
| – | – |
|
|
NVTA
48
DELISTED
Invitae Corporation
NVTA
| $12M | 0.07% |
8,881,104
+479,069
| +6% | +$944K |
|
49
IDEAYA Biosciences
IDYA
$3.83B
| $11.4M | 0.06% |
832,769
-835,586
| -50% | -$13.9M |
|
50
Cabaletta Bio
CABA
$531M
| $11.1M | 0.06% |
1,344,000
| – | – |
|
Similar funds
Julian Baker's Q1 2023 Portfolio in Review
As of Q1 2023, Julian Baker held 118 positions worth $18.4B, up 10% from $16.7B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Julian Baker withdrew a net $958M in Q1 2023, closing 13 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $605M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
Against the trend, Julian Baker opened a new position in Blueprint Medicines worth $15M.
- Julian Baker's largest Q1 2023 buy was Blueprint Medicines: 333,665 shares worth $15M.
- Julian Baker added most to Revolution Medicines in Q1 2023, an estimated $60.8M increase.
- Julian Baker's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $395M.
- Julian Baker fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $605M.
- Julian Baker's ten largest holdings make up 90% of its $18.4B portfolio in Q1 2023.
- Julian Baker opened 7 new positions and closed 13 in Q1 2023.
- Julian Baker's portfolio value rose 10% quarter-over-quarter to $18.4B.
Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.